OIS@AAO 2013

Developing an Effective Dialogue with the FDA

Developing an Effective Dialogue with the FDA

By Tom Salemi | November 14, 2013

Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA.…

Read More
The Ophthalmology Market – “A View from the Public Sector”

The Ophthalmology Market – “A View from the Public Sector”

By Tom Salemi | November 14, 2013

Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for JPMorgan, gladly addresses the audience at the 5th Annual Ophthalmology Innovation Summit…

Read More
2013 Ophthalmology Innovation Summit Innovator Awards

2013 Ophthalmology Innovation Summit Innovator Awards

By Tom Salemi | November 14, 2013

William J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits…

Read More
Going Public – Who, When, and Why?

Going Public – Who, When, and Why?

By Tom Salemi | November 14, 2013

Detailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the…

Read More
The NEI Continues to Explore the Root Cause of Glaucoma

The NEI Continues to Explore the Root Cause of Glaucoma

By Tom Salemi | November 14, 2013

Ophthalmic Innovation 2013 – “A View from the NEI” Paul Sieving, Director for the National Eye Institute, leads the attendees at the 5th Annual Ophthalmology…

Read More
Sustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix

Sustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix

By Tom Salemi | November 14, 2013

Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient…

Read More
Neurotech Transforms the Delivery of Biologics

Neurotech Transforms the Delivery of Biologics

By Tom Salemi | November 14, 2013

Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics…

Read More
ALG1001 Leads Allegro’s Progress in Retinal Diseases

ALG1001 Leads Allegro’s Progress in Retinal Diseases

By Tom Salemi | November 14, 2013

Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for…

Read More
AMAO76 Alleviates the Pressure for Amakem Therapeutics

AMAO76 Alleviates the Pressure for Amakem Therapeutics

By Tom Salemi | November 14, 2013

Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower…

Read More
New Injection Technology Sets the Standard for Icon BioSciences

New Injection Technology Sets the Standard for Icon BioSciences

By Tom Salemi | November 14, 2013

William S. (Sandy) White, President & CEO for Icon BioSciences, discusses the company’s increasing portfolio of products that target most major therapeutic areas of ophthalmology.…

Read More
NPP Meets the Mark for Kala Pharmaceuticals

NPP Meets the Mark for Kala Pharmaceuticals

By Tom Salemi | November 14, 2013

[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation…

Read More
Novaliq Clears the Obstacles in Ocular Track Delivery

Novaliq Clears the Obstacles in Ocular Track Delivery

By Tom Salemi | November 14, 2013

Bernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.